CALGARY, April 29 /PRNewswire-FirstCall/ -- NUCRYST Pharmaceuticals Corp. invites analysts and investors to participate in a briefing on Wednesday, May 6, 2009, with David B. Holtz, Interim President & Chief Executive Officer, and Chief Financial Officer, regarding the Company's 2009 first quarter results.
The briefing, via conference call, is set for 9:00 a.m. EDT. To participate, please call the toll-free number 1-800-814-4860. In addition to standard disclosure over wire services, a news release with the first quarter results will be posted on the NUCRYST web site prior to the call. To listen to the call live on the Internet, please go to http://www.nucryst.com/web_casts.htm.
The briefing will be recorded and available for re-broadcast on demand for seven days by dialing 1-877-289-8525. Callers will need to provide the operator with the following reservation number: 21305201 followed by the number sign. An audio file of the call will also be archived on the NUCRYST web site.
About NUCRYST Pharmaceuticals
NUCRYST Pharmaceuticals Corp. (NASDAQ: NCST; TSX: NCS) develops, manufactures and commercializes medical products that fight infection and inflammation using SILCRYST(TM), its patented atomically disordered nanocrystalline silver technology. NUCRYST licensed world-wide rights for SILCRYST(TM) wound care coating products to Smith & Nephew plc, which markets these products in over 30 countries under their Acticoat(TM) trademark. NUCRYST has developed its proprietary nanocrystalline silver in a powder form, referred to as NPI 32101, for use in medical devices and as an active pharmaceutical ingredient.
Acticoat(TM) is a trademark of Smith & Nephew plc
SILCRYST(TM) is a trademark of NUCRYST Pharmaceuticals Corp.
NUCRYST Pharmaceuticals Corp.
CONTACT: David Wills, Gillian McArdle, Investor Relations, NUCRYST
Pharmaceuticals Corp., (416) 504-8464, info@nucryst.com
